ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $226.42 -0.85%
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- ResMed (RMD) PT Raised to $267 at KeyBanc Following Last Week's NDR
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
